Author Archives: achicotel

About achicotel

Anthony Chicotel is a staff attorney for CANHR. His areas of expertise include the rights of long-term care residents, nursing home litigation, health care decision-making, and conservatorships.

Clarifying Informed Consent in Hospitals

by Anthony Chicotel, CANHR Staff Attorney Among experts in long-term care, there is a consensus that many of the unnecessary and dangerous prescriptions for psychotropic drugs for people with dementia are initiated in hospitals. The acute care environment and quick … Continue reading

Share

There’s Good News and There’s Bad News

by Anthony Chicotel, CANHR Staff Attorney The 4th quarter 2012 nursing home antipsychotic drug data is in and there’s good news and there’s bad news.  The good news is that overall antipsychotic use in nursing homes is down nationally by … Continue reading

Share

CMS Reflects on National Initiative

On January 31, 2013, the Center for Medicare and Medicaid Services (CMS), hosted a 90-minute presentation and question and answer session about its National Initiative to Improve Dementia Care and Reduce the Misuse of Antipsychotic Drugs in Nursing Homes.  You … Continue reading

Share

Medical Board is No Friend to Drugging Victims

The January 9 edition of the San Jose Mercury-News included an article by Anthony Chicotel, CANHR Staff Attorney, about the California Medical Board’s failure to take action in two tragic cases of drugging nursing home residents without their consent or … Continue reading

Share

Listen to Dr. Diana Zuckerman Speak About the Dangers of Antipsychotic Misuse in Nursing Homes

Dr. Zuckerman is the President of the National Research Center for Women and Families and a fellow at the University of Pennsylvania Center for Bioethics. In this podcast, she speaks for 30 minutes about antipsychotic drugs and how and why … Continue reading

Share

The Wheels on Big Pharma’s Bus Go Round and Round

Less than two years ago, CANHR wrote a blog post about Public Citizen’s report recounting the enormous payouts by the pharmaceutical industry to settle cases of mis-marketing and fraudulent charging for various drugs. At the time, big pharma was the … Continue reading

Share

A Fate Worse than Death? Constipation and Informed Consent for Antipsychotic Drugs

by Anthony Chicotel, CANHR Staff Attorney I recently received a transcript of testimony in a legal case involving the unauthorized use of an antipsychotic on an elderly nursing home resident. The testimony is fascinating and reveals how the “informed consent” … Continue reading

Share

No Surprise – Increased Enforcement Reduces Antipsychotic Use

by Anthony Chicotel, CANHR Staff Attorney Last year, Health Economics published a study that closely examined the impact of statewide deficiency citations on the rate of antipsychotic use in nursing homes. As one would expect, the study’s authors found that … Continue reading

Share

California Aims to Reduce Antipsychotics in Nursing Homes by 30%

The California Department of Public Health (CDPH) recently announced a major campaign to reduce the unnecessary use of antipsychotic drugs and improve dementia care in nursing homes. In the announcement, CDPH states that the campaign’s goal is to reduce the … Continue reading

Share

Risperdal More than Doubles Risk of Adverse Events for People with Dementia. Therefore, Keep People with Dementia on Risperdal. Wait . . . what?

by Anthony Chicotel, CANHR Staff Attorney A new study in the October 18, 2012 issue of the venerable New England Journal of Medicine assesses the efficacy of drugging dementia patients with Risperdal versus abruptly discontinuing the drug and substituting a … Continue reading

Share